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Abstract
Background
A debate about the scientific quality of COVID-19 themed research has emerged. We
explored whether the quality of evidence of COVID-19 publications is lower when compared
to nonCOVID-19 publications in the three highest ranked scientific medical journals.
Methods
We searched the PubMed Database from March 12 to April 12, 2020 and identified 559 pub-
lications in the New England Journal of Medicine, the Journal of the American Medical Asso-
ciation, and The Lancet which were divided into COVID-19 (cases, n = 204) and nonCOVID-
19 (controls, n = 355) associated content. After exclusion of secondary, unauthored,
response letters and non-matching article types, 155 COVID-19 publications (including 13
original articles) and 130 nonCOVID-19 publications (including 52 original articles) were
included in the comparative analysis. The hierarchical level of evidence was determined for
each publication included and compared between cases and controls as the main outcome.
A quantitative scoring of quality was carried out for the subgroup of original articles. The
numbers of authors and citation rates were also compared between groups.
Results
The 130 nonCOVID-19 publications were associated with higher levels of evidence on the
level of evidence pyramid, with a strong association measure (Cramer’s V: 0.452, P
<0.001). The 155 COVID-19 publications were 186-fold more likely to be of lower evidence
(95% confidence interval [CI] for odds ratio, 7.0–47; P <0.001). The quantitative quality
score (maximum possible score, 28) was significantly different in favor of nonCOVID-19
(mean difference, 11.1; 95% CI, 8.5–13.7; P <0.001). There was a significant difference in
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the early citation rate of the original articles that favored the COVID-19 original articles
(median [interquartile range], 45 [30–244] vs. 2 [1–4] citations; P <0.001).
Conclusions
We conclude that the quality of COVID-19 publications in the three highest ranked scientific
medical journals is below the quality average of these journals. These findings need to be
verified at a later stage of the pandemic.
Introduction
Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome corona-
virus 2 (SARS CoV-2), and it is a rapidly spreading pandemic that is putting extraordinary
stress on healthcare systems across the globe (For simplicity, we will use COVID-19 in refer-
ence to both the virus and the disease). While everyone waits for a breakthrough of a specific
COVID-19 therapy and an effective vaccine, scientists are redirecting their efforts into
COVID-19–themed research to build up our knowledge of this new disease [1]. A search for
“COVID-19 or SARS-CoV2” in the PubMed database revealed 4,670 publications between
January 1, 2020, and April 12, 2020. This need to publish COVID-19–related findings has been
supported by many Ethical Committees, grant providers, and journal editors, who have ‘fast-
tracked’ COVID-19 publications so that they can be processed at record speed [2–4]. However,
concerns are emerging that scientific standards are not being met.
The first report of COVID-19 transmission in asymptomatic individuals [5] was later con-
sidered to have been flawed, because the patient showed symptoms at the time of transmission
[6]. A similar example occurred in The Lancet, whereby the authors retracted a publication
after admitting irregularities on the first-hand account of the front-line experience of two Chi-
nese nurses [7]. While our article was under review, two major analyses on the use of hydroxy-
chloroquine and cardiovascular mortality associated with COVID-19 were retracted in the
Lancet [8] and the New England Journal of Medicine [9] because source data could not be
verified.
Such situations raise concerns as to the quality of the data, the conclusions presented by the
authors, and the peer review by the editors, due to the pressure to publish highly coveted infor-
mation on COVID-19. The urgency of the outbreak suddenly appears to legitimize key limita-
tions of studies, such as small sample sizes, lack of randomization or blinding, and unvalidated
surrogate endpoints [10, 11].
While clinicians and the public long for effective treatments, a debate about the quality of
this surge of research and the potential violations of scientific rigor has emerged [10, 12, 13].
Despite this massive publication effort, current guidelines remain without any recommenda-
tions on core topics for patient management and care [14, 15]. The combination of clinical
urgency, weak evidence, pre-print publications without prior peer review [16], and public
pressure [17] might lead to inappropriate public health actions and incorrect translation into
clinical practice [18], with the potential for worrying breaches in patient safety [19]. A further
concern is the inflation of publication metrics, particularly in terms of journal impact factors.
Citation-based metrics are used by researchers to maximize the citation potential of their arti-
cles [20]. The expectation of a high citation rate might be used by journals to publish papers of
questionable scientific value on ‘trendy’ topics [21].
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Edwards Lifesciences AG, Fresenius Kabi
(Schweiz) AG, Getinge Group Maquet AG, Hamilton
Medical AG, Pierre Fabre Pharma AG (formerly
known as RobaPharm), PanGas AG Healthcare,
Pfizer AG, Orion Pharma, Teleflex Medical GmbH.
here are no patents, products in development or
marketed products associated with this research to
declare. This does not alter our adherence to PLOS
ONE policies on sharing data and materials.
Abbreviations: CI, confidence interval; COVID-19,
coronavirus disease 2019; QUALSYST, Standard
quality assessment criteria for evaluating primary
research papers from a variety of fields; SARS-
CoV-2, severe acute respiratory syndrome
coronavirus 2.
To date, the quality of COVID-19 publications in the top three general medical journals by
impact factor (i. e. the New England Journal of Medicine, The Lancet and The Journal of the
American Medical Association, represented by an impact factor > 50 for all) has not been for-
mally assessed. We hypothesized that the quality of recent publications on COVID-19 in the
three most influential medical journals is lower than for nonCOVID-19 articles published dur-
ing the same time period. We also determined the early research impact of COVID-19 original
articles versus nonCOVID-19 original articles.
Materials and methods
This report follows the applicable STROBE guidelines for case-control studies.
Publication selection and identification of cases and controls
For the time period of March 12 to April 12, 2020 (i.e., during the early outbreak phase of the
COVID-19 pandemic), we identified all of the publications from the top three general medical
journals by impact factor (the New England Journal of Medicine (NEJM), the Journal of the
American Medical Association (JAMA), and The Lancet). We conducted a PubMed database
search on April 17, 2020, using the following search string: ((("The New England journal of
medicine"[Journal]) OR "Lancet (London, England)"[Journal]) OR "JAMA"[Journal]) AND
("2020/03/12"[Date—Publication]: "2020/04/12"[Date—Publication]). The resulting publica-
tions were stratified into COVID-19–related and nonCOVID-19–related. We matched the
nonCOVID-19 publications with COVID-19 publications according to article types within
each journal, with the exclusion of nonmatching article types. Secondary studies, correspon-
dence letters on previously published articles, unauthored publications, and specific article
types not matching any of the six categories on the levels of the evidence pyramid [22–24]
(e.g., infographic, erratum) were excluded (Fig 1).
Multi-step design
We performed a multi-step 360-degree assessment of the studies. It consisted of their classifi-
cation according to level of evidence for a quantitative appraisal of their methodological qual-
ity using a validated tool, and a narrative analysis of the strengths and weaknesses of the
COVID-19 publications, as is often used in social sciences [25]. Early citation frequencies of
the original articles was determined.
Levels of evidence
All of the publications included were assessed for number of authors and level of evidence. We
used the Oxford Quality Rating Scheme for Studies and Other Evidence [22] to categorize the
level of evidence, as adjusted to include animal and in-vitro research [23, 24]. The highest level
is attributed to research as randomized trials, followed by nonrandomized controlled studies
and cohort trials. The lower levels are represented by descriptive studies, expert opinion, and
animal or in-vitro research, commonly represented in the form of a pyramid [22, 23, 26]. For
secondary analysis, we split the six levels of evidence into the upper and lower halves, which
reflected higher (i.e., 1–3) and lower (i.e., 4–6) levels of evidence, respectively. The number of
authors per publication was counted manually.
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Fig 1. Flow chart of the processing of the publications included in this study. The article types in the NEJM are grouped (by the
publisher) intoOriginal Research (Research Articles and Special Articles for research on economics, ethics, law and health care
systems), Clinical Cases (Brief Reports and Clinical Problem Solving), Review Articles (Clinical Practice Review or Other Reviews),
Commentaries (Editorials, Perspectives, Clinical Implications of Basic Research, Letters to the Editor, Images and Videos in Clinical
Medicine), and other articles (Special Reports, Policy Reports, Sounding Board, Medicine and Society and Case Records of the
Massachusetts General Hospital). The JAMA articles are grouped by the publisher into Research (Original Investigation, Clinical
Trials, Caring for the Critically Ill Patient, Meta-Analysis, Brief Reports and Research letters), Clinical Review and Education
(Systematic Reviews, Advances in Diagnosis and Treatment, Narrative Reviews, Special Communications, Clinical Challenges,
PLOS ONE Quality of COVID-associated clinical research
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Quantitative appraisal using the “Standard quality assessment criteria for
evaluating primary research papers from a variety of fields (QUALSYST)”
After the hierarchical grading of included publications, the original articles (i.e., published as
‘original research articles’ in each of the journals; Fig 1) were defined for further in-depth anal-
ysis using the study quality checklist proposed by Kmet et al. [27]. This checklist is consistent
with the recommendations from the Center for Reviews and Dissemination [28, 29]. Four
authors in pairs (MZ–DB, JBE–BZ; each pair assessing one half of the publications) indepen-
dently assessed the original articles on 14 quality criteria (see S1 File). The 14 items covered
the research question, design, measures to reduce bias, and data reporting and interpretation,
and these were scored according to the degree to which each specific criterion was met (“yes”
= 2; “partial” = 1; “no” = 0; “not applicable” = n/a) with the help of a prespecified manual [27].
The total score ranged from 0 to 28. The summary percentage scores were calculated for each
original article by summing the total score obtained across the applicable items and dividing
by the total possible score (i.e., 28 –[number of “n/a” × 2] ×100). Disagreements between the
reviewers (defined as>2 difference in the total score, or>10% difference in the summary per-
centage scores), were resolved through one round of discussion between each 2-author pair.
Narrative analysis of COVID-19 original articles
The COVID-19 original research articles (n = 13) were assessed in narrative form to report on
their major weaknesses, potential conflicts of interest, and likely influence on further research
and clinical practice.
Citation frequencies
The early citation frequencies were tracked every 5 days from April 25th to May 25th 2020 for
all of the original scientific articles through GoogleScholar [30], to determine how strongly
these COVID-19 original articles had impacted upon further publications, in comparison to
the nonCOVID-19 original articles. A comparison to an original article set in the same time
frame of 2019 was done. Citations per month were calculated to reduce lead time bias. The
Google scholar search engine has been shown to reliably identify the most highly-cited aca-
demic documents [31].
Statistical analysis
The distributions of the COVID-19 and nonCOVID-19 publications on the levels of evidence
pyramid were analyzed using Pearson’s Chi-squared statistics and Cramer’s V as the measure
of strength of association (weak: >0.05; moderate: >0.10; strong: >0.15; very strong: >0.25)
[32]. Further effect size estimations were performed on two by two contingency tables (split by
level of evidence into high and low quality groups) and are reported as odds ratios with 95%
confidence intervals (CI).
The retrospectively calculated sample size for the summary percentage scores [27] to detect
a 20% change from 90 (nonCOVID-19) to 72 (COVID-19), with 4:1 allocation (52:13 original
Diagnostic Test Interpretation, Clinical Evidence Synopsis),Opinion (Viewpoints),Humanities (The Arts and Medicine, A Piece of
My Mind, Poetry) and Correspondence (Letters to the Editor). The Lancet’s articles are grouped into a Red Section (Articles and
Clinical Pictures), a Blue Section (Comments, World Reports, Perspectives, Obituaries, Correspondence, Adverse Drug Reactions
and Department of Error) and a Green Section (Seminars, Reviews, Therapeutics, Series, Hypothesis, Other Departments and
Commissions).
https://doi.org/10.1371/journal.pone.0241826.g001
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articles, respectively) on a t-test, with a standard deviation of 15, 85% power, and 0.05 alpha,
was 8 original articles [33, 34]. Thus, we deemed our collected data sufficient.
We also planned for a secondary analysis if the comparison above resulted in a significant
difference (defined as P <0.05) in the mean percentage scores between the COVID-19 and
nonCOVID-19 original articles. The secondary analysis aimed to compare the 2:1 allocation of
nonCOVID-19:COVID-19 original articles, for which the allocation was carried out with the
26 original articles with the lowest overall percentage scores in the nonCOVID-19 group versus
all of the 13 original articles in the COVID-19 group. The threshold p-value for significance
was set at P <0.025, to adjust for multiple testing.
Assessment of the original articles’ quality is reported as a two-reviewer mean score (95%
CI) and was analyzed using Welch’s t-tests. Hedges’s g was used as the effect size measure
based on a standardized mean difference [35] (small: d = 0.20; medium: d = 0.50; large:
d = 0.80; very large: d = 1.20; huge: d>2.00) [36, 37]. To confirm the reliability of the scoring,
Cronbach’s alpha was calculated for the total score and the summary percentage score (inter-
nal consistency), and the Intraclass Correlation Coefficient with absolute agreement for the
inter-rater reliability. The percentage agreement between the two reviewers was also calculated
for each individual item (see S2 File).
The data distributions were tested for normality with Kolmogorov-Smirnov tests, and are
reported accordingly. Tests between two groups were done with Mann-Withney tests, between
multiple groups with Kurskal-Wallis test. Significance was set at P <0.05 or adjusted for multi-
ple testing. All of the tests were two-tailed. The statistical analysis was performed using SPSS
Statistics 20 (IBM Inc., Armonk, NY, USA) and Prism 8 (GraphPad Software, San Diego, CA,
USA).
Results
Out of 559 publication entries on PubMed for the selected journals, 155 publications on
COVID-19 and 130 publications on other (nonCOVID-19) topics were included in the level of
evidence analysis. The subsequent analysis of quality was performed on 13 COVID-19 original
articles in comparison with 52 nonCOVID-19 original articles (Fig 1).
Levels of evidence and number of authors
The nonCOVID-19 publications were associated with higher quality on the level of evidence
pyramid (P<0.001; Chi squared), with a strong association measure (Cramer’s V: 0.452,
Table 1). When comparing the higher evidence group to the lower evidence group, the
COVID-19 publications were 18-fold more likely (i.e., odds ratio) to be in the lower evidence
group (95% CI: 7.0–47; P<0.001). When comparing only the original articles on the levels of
evidence pyramid (Table 2), the nonCOVID-19 publications were also associated with higher
Table 1. Frequency distribution of the publications included on the levels of evidence pyramid [23, 24].
Study design Level Group COVID-19 (n = 155) [n
(%)]
nonCOVID-19 (n = 130) [n
(%)]
Randomized controlled trial 1 Higher level of
evidence
1 (0.6) 38 (29.2)
Well-designed controlled trial without randomization; prospective
comparative cohort trial
2 0 (0) 2 (1.5)
Case-control study; retrospective cohort study 3 4 (2.6) 9 (6.9)
Case series without or with intervention; cross-sectional study 4 Lower level of
evidence
19 (12.3) 10 (7.7)
Opinion papers; case reports 5 129 (83.2) 69 (53.1)
Animal or in-vitro research 6 2 (1.3) 2 (1.5)
https://doi.org/10.1371/journal.pone.0241826.t001
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quality (P<0.001; Chi squared), with a strong association measure (Cramer’s V: 0.641,
Table 2). When comparing the higher evidence group to the lower evidence group, the
COVID-19 original articles were 26-fold more likely (i.e., odds ratio) to be in the lower evi-
dence group (95% CI: 5.4–120; P <0.001).
Numbers of authors were similar between groups (median [interquartile range]: 3 [2–6.5]
versus 3 [2–13.5]; P = 0.394; Mann-Whitney). In an a posteriori subgroup analysis in the lower
evidence group (adjusted threshold p-value as P<0.017), there were significantly more
authors in the COVID-19 publications (median [interquartile range]: 3 [2–6]) than in the non-
COVID-19 publications (median: 2 [1–3]) (P<0.001; Mann-Whitney). Obvious outliers were
a NEJM case report [38] with 35 authors, an opinion correspondence piece in The Lancet [39]
with 29 authors, and a comment piece in The Lancet with 77 authors in a coalition [40].
Quantitative appraisal
Due to>2 difference in the total scores, or>10% difference in the summary percentage scores,
the reviewer pairs discussed 8 (of 32) and 12 (of 33), respectively, of the original articles after
the individual scoring. The internal consistency reliability of the total score was 0.987, and of
the summary percentage score was 0.964 (Cronbach’s alphas) for the reviewer pair MZ–DB,
and 0.988 and 0.928, respectively, for the reviewer pair JBE–BZ (P< 0.001, for all). The inter-
rater reliabilities of the total scores was 0.975, and the summary percentage score was 0.930
(Intraclass Correlation Coefficient, absolute agreement) for pair MZ–DB, and 0.974 and 0.860,
respectively, for pair JBE–BZ (Intraclass Correlation Coefficient, absolute agreement)
(P< 0.001, for all).
The mean total scores in the COVID-19 and nonCOVID-19 groups were 12.6 (95% CI
10.1–15.1) and 23.7 (95% CI 22.9–24.6) respectively (Fig 2A), and the mean summary percent-
age scores were 71.8% (95% CI 62.4–81.1) and 91.1% (95% CI 89.0–93.2), respectively (Fig
2C). The mean total score and the mean summary percentage scores were significantly differ-
ent between the groups, favoring the nonCOVID-19 original articles (P<0.001, for both;
Welch’s t-test; Hedges’ g = 3.37, 2.02, respectively). For the total scores, the difference between
the means was 11.1 (95% CI 8.5–13.7; P<0.001), and for the summary percentage scores,
19.3% (95% CI 9.8%–28.8%; P <0.001). Also, in the secondary analysis, when the COVID-19
original articles were compared to the lower quality half of the nonCOVID-19 original articles
(i.e., the 26 scoring lower instead of all 52), the differences in the mean total scores (Fig 2B;
12.6 [95% CI 10.1–15.1] vs 21.4 [95% CI 20.4.1–22.3] points, respectively; P = 0.008; Welch’s t-
test; Hedges’ g = 2.86) and the mean summary percentage scores (Fig 2D; 71.8% [95% CI 62.4–
81.1] vs 85.6% [95% CI 82.8–88.5], respectively; P <0.001; Welch’s t-test; Hedges’ g = 1.31)
were significant. For this secondary analysis, the threshold P value for significance was set at
p = 0.025.
Table 2. Frequency distribution of the original articles on the levels of evidence pyramid [23, 24].
Study design Level Group COVID-19 (n = 13) [n
(%)]
nonCOVID-19 (n = 52) [n
(%)]
Randomized controlled trial 1 Higher level of
evidence
1 (7.7) 38 (73.1)
Well-designed controlled trial without randomization; prospective
comparative cohort trial
2 0 (0) 1 (1.9)
Case-control study; retrospective cohort study 3 2 (15.4) 7 (13.5)
Case series without or with intervention; cross-sectional study 4 Lower level of
evidence
9 (69.2) 6 (11.5)
Opinion papers; case reports 5 1 (7.7) 0 (0)
Animal or in-vitro research 6 0 (0) 0 (0)
https://doi.org/10.1371/journal.pone.0241826.t002
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In a secondary sensitivity analysis that also included research letters, the mean total scores
in the COVID-19 (n = 21) and nonCOVID-19 (n = 55) groups were 12.3 (95% CI 10.6–14)
and 23.3 (95% CI 22.2–24.2) respectively, and the mean summary percentage scores were
72.6% (95% CI 66.1–79.1) and 90.9% (95% CI 88.9–92.9), respectively. The mean total score
Fig 2. Quantitative appraisal of the quality of the COVID-19 versus nonCOVID-19 original articles. The
“Standard quality assessment criteria for evaluating primary research papers from a variety of fields”25 was used, for a
maximum total score of 28. (A, C) Primary analysis for mean total scores (A) and mean summary percentage scores
(C) for all COVID-19 (n = 13) and nonCOVID-19 (n = 52) original articles. (B, D) Secondary analysis for mean total
scores (B) and mean summary percentage scores (D) that included all of the COVID-19 original articles (n = 13) and
the lower quality half of the nonCOVID-19 original articles (n = 26). Data are means with 95% CI. An adjusted
threshold P value of 0.025 defines significance (adjusted for multiple testing. Welch’s t-tests).
https://doi.org/10.1371/journal.pone.0241826.g002
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and the mean summary percentage scores were significantly different between the groups,
favoring the nonCOVID-19 original articles (P <0.001, for both; Welch’s t-test; Hedges’
g = 2.98, 1.87, respectively). For the total scores, the difference between the means was 11.0
(95% CI 9.1–12.9; P <0.001), and for the summary percentage scores, 18.3% (95% CI 11.6%–
25.0%; P <0.001).
Citation frequency
There was a significant difference in the median number of citations according to GoogleScho-
lar at each of the seven dates tested, favoring COVID-19 original research papers (P<0.001,
for all; Mann-Whitney, Table 3). A comparison to a set of original articles from the same dates
in 2019 revealed 53 (25 to 90) citations in 2019 vs. 334 (222 to 1001) citations for COVID arti-
cles in August 2020 and 10 (4 to 18) for non COVID articles (p<0.002 for all comparisons).
When corrected for lead-time with citations per month, the articles in 2019 have 4 (2 to 6)
cites per month, the non-Covid articles in 2020 2.5 (1 to 4.5) without significance. The COVID
articles in 2020 have 83.5 (55 to 250) cites per month (p<0.001).
Narrative appraisal
The major weaknesses of the 13 COVID-19 original research articles were assessed (Table 4).
The selection included one randomized trial [41], four retrospective cohort studies or case
series [42–45], five epidemiological descriptive studies [46–50], three epidemiologic modeling
studies [51–53], with most of the designs reflecting low grades of evidence [22]. Most of these
studies had limitations in terms of missing data or under-reporting. The randomized trial was
not blinded. Ten studies showed no apparent conflicts of interest. Two studies were based on
data collected by the World Health Organization [51, 52], and in another study [54] a pharma-
ceutical company screened the patients for treatment, collected the data, and supported the
trial financially. Two studies had a patient:author ratio <1 [43, 46]. Two studies were close to 1
[55, 56]. Three studies were considered not relevant for further research [46, 48, 55], and four
studies were deemed not relevant for clinical practice [43, 46, 55, 56], because the findings
were neither new nor generalizable. The 13 COVID-19 original articles have already been
cited in 52 sets of published guidelines.
Discussion
The main finding of our study is that the COVID-19–related research in these highly ranked
medical journals is of lower quality than research on other topics in the same journals for the
Table 3. Google Scholar citations of original articles published between March 12 and April 12, 2020.
Date Original articles citations P value�
COVID-19 (n = 13) nonCOVID-19 (n = 52)
April 25 33 (14–212) 2 (1–3) <0.001
April 30 45 (30–244) 2 (1–4) <0.001
May 5 65 (41–290) 2 (1–4) <0.001
May 10 88 (48–328) 2 (1–5) <0.001
May 15 123 (59–390) 2.5 (1–5) <0.001
May 20 139 (64–435) 3 (1.3–6) <0.001
May 25 149 (73–512) 3 (1.3–7) <0.001
Data are median (interquartile range)
� Mann-Whitney tests
https://doi.org/10.1371/journal.pone.0241826.t003
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Table 4. Narrative assessment of the quality of the COVID-19 original articles.
Reported study Major weaknesses Conflict of interest Patient:
author
(ratio)
Should influence further
research?
Should influence clinical
practice?
Citation
rate as of
April 30
Bhatraju et al. Covid-19 in
critically ill patients in the
Seattle region—case series
[55]
Design implies a low grade
evidence (case-series; no
generalizable or
representative information).
Patients presented with
similar respiratory
symptoms and had similar
mortality rate to patients
described in reports from
China. Incomplete
documentation of
symptoms and missing
laboratory testing
None apparent 24:18
(1.33)
No. Similar data across
Chinese and European
cohorts.
No. No new findings.
Incorporated into two
guideline documents
86
Cao et al. A trial of
lopinavir-ritonavir in adults
hospitalized with severe
COVID-19 [41]
Some exclusion criteria were
vague (physician decision
when involved in the trial as
not in the best interest of the
patients, presence of any
condition that would not
allow protocol to be
followed safely). No
blinding. No placebo
prepared.
None apparent 199:65
(3.06)
Yes. Pursuing more trials
with lopinavir-ritonavir
not necessary.
Yes. Lopinavir-ritonavir
treatment added to standard
supportive care not associated
with clinical improvement or
mortality in seriously ill
patients with COVID-19, and
therefore should not be used
for treatment.
389
Ghinai et al. First known
person-to-person
transmission of severe
acute respiratory syndrome
coronavirus 2 (SARS-CoV-
2) in the USA [46]
Design implies low grade
evidence (case-report; no
generalizable or
representative information).
Incomplete documentation.
Epidemiological design
performed before
implementation of CDC
guidelines (not comparable
to future investigations).
None apparent 2:38
(0.05)
No. Epidemiological
design performed before
implementation of CDC
guidelines (methodology
not comparable to future
investigations).
No. Described before in
another country. Incorporated
into Position Paper on
COVID-19 of the
EASL-ESCMID
38
Gilbert et al. Preparedness
and vulnerability of African
countries against
importations of COVID-19:
a modelling study [51]
Design implies low grade
evidence (epidemiologic
modeling study;
anticipatory). Study did not
state limitations. Complex
analysis.
Yes. WHO
supported
N/A Yes. Should influence
public health measures
and research for
implementation and
effectiveness
Yes. Should influence public
health measures. Mainly
Africa-derived research
98
Grasselli et al. Baseline
characteristics and
outcomes of 1591 patients
infected with SARS-CoV-2
admitted to ICUs of the
Lombardy region, Italy [42]
Design implies low grade
evidence (Case-series). Data
acquired telephonically.
Large amounts of missing
data. ICU mortality
reported while 58% were
still on ICU.
None apparent 1591:21
(75.76)
Yes. Baseline data for
Europe.
Yes. Representative cohort to
inform clinical practice.
Incorporated into a Position
Paper of the German Society
of Pneumology on treatment
for COVID-19 and in
guideline from ENT-UK for
safe tracheostomy of COVID-
19 patients.
51
Grein et al. Compassionate
use of remdesivir for
patients with severe
COVID-19 [54]
Design implies low grade
evidence (Case-Series). No
sample size calculation/
small sample size/
underpowered study.
Limited number of collected
laboratory measures.
Missing data. No control
group.
Yes. Medication
supplied after
request to Gilead.
Gilead funded trial,
collected data, and
decided which
patients got drug
53:56
(0.94)
Yes. Findings from these
uncontrolled data
informed by the ongoing
randomized, placebo-
controlled trials of
remdesivir therapy for
COVID-19.
Currently no. Data too low
quality to influence clinical
practice, concerns regarding
patient safety. Included in
four sets of guidelines.
42
(Continued)
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same period of time, with strong measures for effect size. We also demonstrated that the num-
ber of publications on COVID-19 alone is almost the same as the number of publications on
all other topics. These findings provide evidence for the debate on the scientific value, ethics,
and information overload of COVID-19 research [10, 13, 19].
Table 4. (Continued)
Reported study Major weaknesses Conflict of interest Patient:
author
(ratio)
Should influence further
research?
Should influence clinical
practice?
Citation
rate as of
April 30
Kandel et al. Health
security capacities in the
context of COVID-19
outbreak: an analysis of
International Health
Regulations annual report
data from 182 countries
[52]
Design implies a low grade
evidence (epidemiologic
modelling study;
anticipatory). Study does
not state limitations.
Complex analysis.
Yes. WHO
supported
N/A Yes. Should influence
public health measures
and research for
implementation and
effectiveness
Yes. Should influence public
health measures and research
for implementation and
effectiveness.
24
Leung et al. First-wave
COVID-19 transmissibility
and severity in China
outside Hubei after control
measures, and second-wave
scenario planning: a
modelling impact
assessment [53]
Design implies a low grade
evidence (epidemiologic
modelling study;
anticipatory). Under-
reporting from national
sources. Complex analysis.
None apparent N/A Yes. Should influence
public health measures
and research for
implementation and
effectiveness
Yes. Should influence public
health measures and research
for implementation and
effectiveness.
11
Li et al. Early transmission
dynamics in Wuhan,
China, of novel
Coronavirus-infected
pneumonia [47]
Design implies a low grade
evidence (epidemiologic
descriptive study). Missing
values, probably
underreporting.
None apparent 425:45
(9.44)
Yes. First estimate of
pandemic dynamics.
Yes. Representative cohort
can inform clinical practice.
Included in eight sets of
guidelines
2027
McMichael et al.
Epidemiology of COVID-
19 in a long-term care
facility in King County,
Washington [48]
Design implies a low grade
evidence (epidemiologic
descriptive study). Missing
values.
None apparent 147/31
(4.74)
No. Similar data to other
cohorts, no
generalizability of results.
Yes. Representative cohort
can inform clinical practice.
Included in two societal
recommendations for
protecting against and
mitigation of COVID-19
pandemic in long-term care
facilities.
45
Pan et al. Association of
public health interventions
with the epidemiology of
the COVID-19 outbreak in
Wuhan, China [49]
Design implies a low grade
evidence (epidemiologic
descriptive study). Missing
values. Questionable
findings (letter from
Lipsitch et al.) [63]
None apparent N/A Yes. Should influence
public health measures
and research for
implementation and
effectiveness.
Yes. Should influence public
health measures and research
for implementation and
effectiveness.
24
Pung et al. Investigation of
three clusters of COVID-19
in Singapore: implications
for surveillance and
response measures [50]
Design implies a low grade
evidence (epidemiologic
descriptive study). Small
sample size. Missing values.
Recall bias.
None apparent 36:20
(1.80)
Might influence public
health measures to contain
clusters.
No. Data too low quality to
influence clinical practice (no
generalizability).
36
Zhou et al. Clinical course
and risk factors for
mortality of adult
inpatients with COVID-19
in Wuhan, China: a
retrospective cohort study
[44]
Small sample. Missing
values.
None apparent 191:19
(10.05)
Yes. Early description of
clinical course. Findings
might change with
ongoing pandemic and for
other health systems
Yes. Representative cohort
can inform clinical practice.
Included in 33 sets of
guidelines from different
societies (all continents
represented).
1085
CDC: Center for Disease Control; N/A, not applicable
https://doi.org/10.1371/journal.pone.0241826.t004
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There are several limitations to the present study. Even though our data were less than a
month old at first submission, the results may soon become obsolete, as new COVID-19
research emerges on a daily basis. We tried to overcome potential bias with a clear search strat-
egy and simple analysis, making our findings highly reproducible. We chose Lander’s method
because it allowed inclusion of in-vitro and animal research [23], and we refined the hierarchi-
cal grading of the level of evidence using a quantitative tool [27]. Given the vast choice [57], we
chose the QUALSYST-tool on the basis that it allows assessment and comparison across multi-
ple study types [27]. Even when the summary scoring might be biased for a methodological
quality assessment [57], “composite quality scales can provide useful overall assessments when
comparing populations of trials” [57]. The QUALSYST tool has been validated and is easy to
use. This may facilitate additional similar studies at a later stage of the pandemic. Compared to
an in-depth analysis of a study’s peer-review process prior to acceptance for publication, it
must remain very superficial. We did not expand our analysis to check source data. The data
scandal leading to retraction of two major studies [8, 9] emerged while our article was under
peer-review. The tools we used would not be suitable to have detected this. Public data reposi-
tories and an “open science” approach may facilitate data validation [58].
The imbalance between the two cohorts in our study might come from a lack of random-
ized trials and a proliferation of opinion articles and cluster descriptions for the COVID-19
publications. It can be argued that in the early phases of a pandemic, case-defining reports are
mandatory for the evolving dynamics of the outbreak and that such studies will suffer from the
usual limitations of initial investigations, and will score lower on quality, even when they are
carried out to high standards. However, in our secondary analysis, after exclusion of the high-
est-quality nonCOVID-19 publications, the significant quality difference remained. One
might argue that a comparison to a historical control group, for example the same time frame
in 2019, when there was no pandemic effect on research, would have been more appropriate.
Our hypothesis was that COVID-related research showed lower quality than non-COVID
research. A historical control group may introduce a selection bias, since conditions for
research then would be clearly different. We would therefore argue that the control group has
to be subject to the same conditions as the test group, when methodological quality is assessed.
This may be different for other endpoints like total research output. In line with our results,
Stefanini et al reported—in an oral presentation at the European Society of Cardiology Con-
gress 2020—similar findings of lower quality associated with COVID-19 in the same journals
and timeframe as our work with a historical control group of 2019. So, both historical and con-
temporary control groups lead to the same conclusions.
The COVID-19 thematic per semight have attracted more readers and researchers, which
will have led to more citations and greater incorporation into secondary studies, as we have
also demonstrated. Such a ‘double-whammy’ of lower-quality literature and high dissemina-
tion potential can have grave consequences, as it might urge clinicians to take actions and use
treatments that are compassionately based but supported by little scientific evidence. Indeed,
apart from exposing patients to potential side effects of some drugs [46, 59, 60], treatment
strategies based on case reports are generally futile [61]. While multiple diagnostic, therapeu-
tic, and preventive interventions for COVID-19 are being trialed [62], clinicians should some-
times resist the wish “to at least do something”, and to maintain clinical equipoise while fully
gathering and evaluating the data that are available [12, 61]. This responsibility needs to be
shared by the high-impact journals, which should continue to maintain publication standards
as for other nonCOVID-19 research. It must be acknowledged though, that a citation does not
necessarily need to be positive for a study or author, if the context, i. e. criticism or discussions
about retractions and corrections, of the citations are considered. This is beyond the scope of
our work.
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The pandemic took a toll on all aspects of life. Clearly, journal reviewers were restricted
in the time they were able to invest into their valuable, voluntary and honorary work. To
what extent changes in their practices have occurred is not accessible for us, since the peer-
review process was blind and confidential. Assessing of journals with open peer review dur-
ing the pandemic may shed light on such phenomena, but this was not the scope of our
study.
We also demonstrated a worrying trend of increasingly long authorships in lower quality
COVID-19 publications, with the almost ‘anecdotical’ findings of some of the publications
actually having more authors than patients [38, 43, 46]. The current demand for publications
appears to have led authors to send their COVID-19 findings to higher-impact journals. As the
authors of the present report, we are exposed to the same allegations.
At present, we can only issue a plea to both authors and editors to maintain their ethical
and moral responsibilities in terms of the International Committee of Medical Journal Editors
authorship standards. Being at the forefront of medical discovery, these journals should not
publish lower quality findings just to promote citations. The risk of bias and unintended con-
sequences for patients is relevant [61], and scientific standards must not be ‘negotiable’[10].
Conclusions
The quality of the COVID-19–related research in the top three scientific medical journals is
below the quality average of these journals. Unfortunately, our numbers do not contribute to a
solution as to how to preserve scientific rigor under the pressure of a pandemic.
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